A randomized placebo-controlled Phase 2 study found that lysergic acid diethylamide (LSD)–assisted therapy yielded significant reductions in anxiety and depression symptoms for up to 16 weeks. The data from the study was recently published in the peer-reviewed Biological Psychiatry. Researchers at the University Hospital Basel (UHB) conducted the investigator-initiated study, which involved 42 patients. While…